Data generated by diabetes devices—including continuous glucose monitors, smart pens, and insulin pumps—are fundamental to ...

The digital diabetes developer Glooko has collected $100 million and a new CEO to help boost the trajectory of its data management platform. The company said that after a global search, it has ...

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...

Eli Lilly and Company's strong Phase 3 diabetes drug results boost its GLP-1 franchise. Click for my updated look at LLY ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The tool predicts changes in A1C in the next 90 days and ...

A statistical model based entirely on claims data can accurately predict 30-day hospital readmission in Medicaid patients with diabetes. Objectives: Readmission is common and costly for hospitalized ...

India has launched its first-ever diabetes biobank in Chennai, a major step toward understanding and tackling one of the country's most pressing health concerns. This groundbreaking initiative is a ...

FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland (Reuters) -Lexicon Pharmaceuticals said on Monday the U.S. Food and Drug Administration requires more time to review the ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...

Over time, you notice your blood sugar levels landing outside the 70 to 140 mg/dL range. This can be a clue to insulin ...